You are here
Angelo Di Leo, MD, PhD
“Sandro Pitigliani” Medical Oncology Unit and Oncology Department, Prato Hospital,
Tumour Institute of Tuscany (ITT), Prato, Italy
Angelo Di Leo is currently Head of the Sandro Pitigliani Medical Oncology Unit, and Chair of the Oncology Department, at the Hospital of Prato, Istituto Toscano Tumori, in Prato, Italy, positions he took up in September 2003. After graduating in medicine and surgery at the University of Palermo (Italy) in 1988, he received his postgraduate diploma in medical oncology from the University of Pavia (Italy) in 1992 and his European certification in medical oncology in 1996. Dr Di Leo trained at the National Cancer Institute in Milan, Italy, and worked there for 7 years until 1996. From 1996 to 2003, he worked at the Chemotherapy Unit of the Jules Bordet Institute (IJB) in Brussels, Belgium, where in 1997 he was appointed senior staff member and Medical Director of the Breast European Adjuvant Studies Team (BrEAST).
Dr Di Leo’s main research interest is breast cancer and he has coordinated a number of international, pivotal phase 3 trials on new adjuvant therapies. He is also heavily involved in the evaluation of molecular markers with potential predictive value to treat breast cancer patients.
Dr Di Leo is the author of many peer-reviewed articles and has lectured extensively at national and international meetings. He is a member of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) steering committee, a member of the Scientific Advisory Council of Susan G. Komen® and a member of the Executive Board of the Breast International Group (BIG). He has also served as a member of the American Society of Clinical Oncology (ASCO) Grants Selection Committee (GSC) (2006–2009) and of the ASCO Education Committee (2012–2014).